Search

Your search keyword '"Rolf A"' showing total 1,529 results

Search Constraints

Start Over You searched for: Author "Rolf A" Remove constraint Author: "Rolf A" Journal blood Remove constraint Journal: blood
1,529 results on '"Rolf A"'

Search Results

1. NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression

3. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determine myeloma CAR-T outcomes

4. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study

5. Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

6. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis

7. Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein

8. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells

9. Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma

10. Transfusion-related acute lung injury: incidence and risk factors.

13. Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

15. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

16. A human genome editing–based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features

17. High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

20. Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase

21. BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease

23. Trial in Progress: An Open-Label, Multi-Center, First in Human, Phase 1/2a Trial to Evaluate the Safety and Preliminary Efficacy of Autologous Tolerogenic Dendritic Cells Ex Vivo Loaded with Recombinant Factor VIII (FVIII) in Adults with Congenital Hemophilia a (HA) with Neutralizing Antibodies to FVIII and Having Failed Immune Tolerance Induction (ITI)

24. High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

26. Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype

29. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

31. Procoagulant activities of skeletal muscle and cardiac myosins require both myosin protein and myosin-associated anionic phospholipids

32. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells

33. Trial in Progress: An Open-Label, Multi-Center, First in Human, Phase 1/2a Trial to Evaluate the Safety and Preliminary Efficacy of Autologous Tolerogenic Dendritic Cells Ex Vivo Loaded with Recombinant Factor VIII (FVIII) in Adults with Congenital Hemophilia a (HA) with Neutralizing Antibodies to FVIII and Having Failed Immune Tolerance Induction (ITI)

34. BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease

40. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)

43. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

47. ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling

Catalog

Books, media, physical & digital resources